Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Leukemia - A Competitive Analysis to New Products, Portfolio Planning, Licensing & Acquisition Through Pipeline Benchmarking

Published by: BioSeeker Group AB

Published: Apr. 3, 2009 - 512 Pages


Table of Contents


1 Executive Summary

2 About Cancer Highlights

3 Methodologies

4 Table of Contents

4.1 List of Figures

4.2 List of Tables

5 Introduction

6 Single Drug Target Benchmarking from the Leukemia Pipeline

6.1.1 Carboxy-Lyase Activity Targets
6.1.2 Catalytic Activity Targets

6.1.3 Cell Adhesion Molecule Activity Targets

6.1.4 Chaperone Activity Targets

6.1.5 Cysteine-Type Peptidase Activity Targets

6.1.6 Cytokine Activity Targets

6.1.7 Deaminase Activity Targets

6.1.8 DNA Repair Protein Targets

6.1.9 DNA Topoisomerase Activity Targets

6.1.10 DNA-Directed DNA Polymerase Activity Targets

6.1.11 DNA-Methyltransferase Activity Targets

6.1.12 G-Protein Coupled Receptor Activity Targets

6.1.13 Growth Factor Activity Targets

6.1.14 Hydrolase Activity Targets

6.1.15 Kinase Activity Targets

6.1.16 Kinase Regulator Activity Targets

6.1.17 Ligand-Dependent Nuclear Receptor Activity Targets

6.1.18 Ligase Activity Targets

6.1.19 Lipid Kinase Activity Targets

6.1.20 MHC Class I Receptor Activity Targets

6.1.21 Molecular Function Unknown Targets

6.1.22 Motor Activity Targets

6.1.23 Oxidoreductase activity Targets

6.1.24 Phosphoric diester hydrolase activity Targets

6.1.25 Phosphorylase activity Targets

6.1.26 Protein Binding Targets

6.1.27 Protein serine/threonine kinase activity Targets

6.1.28 Protein tyrosine phosphatase activity Targets

6.1.29 Protein-tyrosine kinase activity Targets

6.1.30 Receptor Activity Targets

6.1.31 Receptor Signaling Complex Scaffold Activity Targets

6.1.32 RNA Binding Targets

6.1.33 RNA-Directed DNA Polymerase Activity Targets

6.1.34 Serine-Type Peptidase Activity Targets

6.1.35 Structural Constituent Of Cytoskeleton Targets

6.1.36 Superoxide dismutase activity Targets

6.1.37 T Cell Receptor Activity Targets

6.1.38 Transcription Factor Activity Targets

6.1.39 Transcription Regulator Activity Targets

6.1.40 Transferase Activity Targets

6.1.41 Translation Regulator Activity Targets

6.1.42 Transmembrane receptor activity Targets

6.1.43 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets

6.1.44 Transporter activity Targets

6.1.45 Other Targets

6.2 The Cancer Genome Project and Leukemia Targets
6.2.1 Leukemia Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer
6.3 Structure-based Drug Design in Leukemia is Stimulated by Available Structure Data on Biological Targets
6.4 Target-Target Interactions among Identified Leukemia Targets

6.5 The Drug-Target Interactome

6.6 Protein Expression Levels of Identified Drug Targets of Leukemia Drugs

6.7 Pathway Analysis of Leukemia Drug Targets

7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug

7.1 Pre-Registration to being Marketed: New and Unique Drug Target Combinations of the Leukemia Pipeline

7.2 Phase III Clinical Development: New and Unique Drug Target Combinations of the Leukemia Pipeline

7.3 Phase II Clinical Development: New and Unique Drug Target Combinations of the Leukemia Pipeline

7.4 Phase I Clinical Development: New and Unique Drug Target Combinations of the Leukemia Pipeline

7.5 Preclinical Development: New and Unique Drug Target Combinations of the Leukemia Pipeline

7.6 Development Profiles of All Leukemia Drug Target Combinations

8 Compound Strategies at Work: Competitive Benchmarking of Leukemia Pipeline by Type of Compound

8.1 Small Molecules

8.1.1 Background
8.1.2 Targets in Leukemia

8.2 Peptide/Protein Drugs
8.2.1 Background
8.2.2 Targets in Leukemia

8.3 Antibodies and Antibody-like Structures
8.3.1 Background
8.3.2 Targets in Leukemia

8.4 Nucleic Acid Therapies
8.4.1 Background
8.4.2 Targets in Leukemia

8.5 Gene Therapy
8.5.1 Background
8.5.2 Targets in Leukemia

8.6 Drug Delivery and Nanotechnology
8.6.1 Background
8.6.2 Targets in Leukemia

8.7 Compound Strategies based on Sub-Cellular Localization of Leukemia Drug Targets
9 Portfolio Planning: Competitive Benchmarking of Leukemia Pipeline by Investigator


9.1 4SC

9.2 Abbott

9.3 Abiogen

9.4 Actinium Pharmaceuticals

9.5 AEgera

9.6 Aeterna Zentaris

9.7 Agennix

9.8 Alexion

9.9 Alfa Wassermann

9.10 Ambit Biosciences

9.11 Amgen

9.12 Antigenics

9.13 Antisoma

9.14 Ariad

9.15 Arno Therapeutics

9.16 Array BioPharma

9.17 Asahi Kasei Pharma

9.18 Ascenta Therapeutics

9.19 Astellas

9.20 Astex Therapeutics

9.21 AstraZeneca

9.22 Attenuon

9.23 Bayer

9.24 BioCryst Pharmaceuticals

9.25 Biogen Idec

9.26 Bioton

9.27 Boehringer Ingelheim

9.28 Bristol-Myers Squibb

9.29 BTG

9.30 Calistoga Pharmaceuticals

9.31 Callisto Pharmaceuticals

9.32 Celator Pharmaceuticals

9.33 Cell Genesys

9.34 Cell Therapeutics

9.35 Cephalon

9.36 CJ Corp

9.37 Clavis Pharma

9.38 Curacyte

9.39 Cyclacel

9.40 Cylene Pharmaceuticals

9.41 CytImmune Sciences

9.42 Cytokinetics

9.43 Daiichi Sankyo

9.44 Dainippon Sumitomo Pharma

9.45 Dara Biosciences

9.46 Deciphera Pharmaceuticals

9.47 Dong-A

9.48 Eleos

9.49 Eli Lilly

9.50 Enzon

9.51 EpiCept

9.52 Exelixis

9.53 ExonHit Therapeutics

9.54 Gemin X Pharmaceuticals

9.55 Genentech

9.56 Genmab

9.57 Genta

9.58 Genzyme

9.59 Geron

9.60 GlaxoSmithKline

9.61 Gloucester Pharmaceuticals

9.62 GlycoGenesys

9.63 Hayashibara

9.64 Hoffmann-La Roche

9.65 ImClone Systems

9.66 Immunomedics

9.67 Innate Pharma

9.68 Innovive

9.69 Isis Pharmaceuticals

9.70 Italfarmaco

9.71 Johnson & Johnson

9.72 Kanisa

9.73 Kyowa Hakko Kirin

9.74 LG Life Sciences

9.75 Lorus Therapeutics

9.76 MAT Biopharma

9.77 MaxCyte

9.78 Meda

9.79 Medarex

9.80 MethylGene

9.81 Micromet

9.82 MorphoSys

9.83 NanoMed Pharmaceuticals

9.84 Nerviano Medical Sciences

9.85 National Institute of Health (USA)

9.86 Nippon Shinyaku

9.87 Novartis

9.88 Novogen

9.89 PDL BioPharma

9.90 Peplin

9.91 Pfizer

9.92 Pharmacyclics

9.93 PharmaMar

9.94 PIERIS Proteolab

9.95 Rigel

9.96 Sanofi-Aventis

9.97 Santaris Pharma

9.98 SBIO

9.99 Schering-Plough

9.100 SciGen

9.101 Seattle Genetics

9.102 Sepal Pharma

9.103 Servier

9.104 Shantha Biotechnics

9.105 Sidus

9.106 Spirogen

9.107 Stemline Therapeutics

9.108 SuperGen

9.109 Supratek Pharma

9.110 Swedish Orphan

9.111 SymBio Pharmaceuticals

9.112 Takeda

9.113 Teva

9.114 TopoTarget

9.115 Trion Pharma

9.116 Trubion

9.117 Vertex Pharmaceuticals

9.118 Vion Pharmaceuticals

9.119 VioQuest

9.120 Wyeth

9.121 Yamasa Corporation

9.122 Zenyaku Kogyo

9.123 ZymoGenetics

9.124 Non-Industrial Sources

10 Disclaimer

11 Drug Index

12 Company Index

4.1 List of Figures

Figure 1: Overall Breakdown of Included Leukemia Pipeline by Sub-indication and Stage of Development

Figure 2: Visualization of Target-Target Interactions Among Leukemia Drug Targets

Figure 3: The Drug-Protein Interactome of Leukemia Drugs - The Main Cluster

Figure 4: The Drug-Protein Interactome of Leukemia Drugs - Smaller Clusters

Figure 5: Head-to-Head Targeting Interactome of Leukemia Drugs

Figure 6: Distribution of Compound Types among Leukemia Drugs

Figure 7: Primary Sub-cellular Localization of Drug Targets

4.2 List of Tables

Table 1: Overview of Drug Target Profile Themes

Table 2: Drug Targets of Leukemia Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the

Cancer Gene Census

Table 3: Identity of Leukemia Drug Targets with Available Biological Structures

Table 4: Number of Target-Target Interactions among Leukemia Drug Targets

Table 5: Drug-Protein Interactome Clusters

Table 6: Leukemia Drug Targets with Available Protein Expression Profiles

Table 7: Pathway Summary

Table 8: Drug Targets without any Identified Assigned Pathways

Table 9: Pathway Profile According to BioCarta of Leukemia Drug Targets

Table 10: Pathway Profile According to KEGG of Leukemia Drug Targets

Table 11: Pathway Profile According to NetPath of Leukemia Drug Targets

Table 12: Number of Drug Target Combinations by the Highest Developmental Stage and Uniqueness

Table 13: Top 5 Competitive Leukemia Targets

Table 14 New and Unique Leukemia Targets in Pre-Registration to Marketed

Table 15: New and Unique Leukemia Targets in Phase III Clinical Development

Table 16: New and Unique Leukemia Targets in Phase II Clinical Development

Table 17 New and Unique Leukemia Targets in Phase I Clinical Development

Table 18: New and Unique Leukemia Targets in Preclinical Development

Table 19: The Progression, Maturity and Competitive Comparison of Leukemia Drug Target Combinations in Development

Table 20: Number of Leukemia Drug Target Mixes Reported by Compound Strategy

Table 21: Number of Head-to-head Competing Small Molecule Drugs for the Treatment of Leukemia by Drug Target

Table 22: Drug Targets of Small Molecule Drugs in Leukemia

Table 23: The Competition Through Close Mechanistic Approximation Between Small Molecule Drugs in Leukemia

Table 24: Drug Targets of Peptide Based Drugs in Leukemia

Table 25: Drug Targets of Protein Based Drugs in Leukemia

Table 26: Drug Targets of Antibodies and Antibody-like Drugs in Leukemia

Table 27: The Competition Through Close Mechanistic Approximation Between Antibody Drugs in Leukemia . 312

Table 28: Drug Targets of Nucleic Acid Therapies in Leukemia

Table 29: Vectors in Gene Therapy

Table 30: Drug Targets of Gene Therapies in Leukemia

Table 31: Drug Targets with New Drug Delivery Strategies in Leukemia

Table 32: Compound Strategies based on Sub-Cellular Localization of Leukemia Drug Targets

Table 33: 4SC's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 34: Abbott's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 35: Abiogen's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 36: Actinium Pharmaceuticals' Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 37: AEgera's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 38: Aeterna Zentaris' Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 39: Agennix's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 40: Alexion's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 41: Alfa Wassermann's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 42: Ambit Biosciences' Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 43: Amgen's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 44: Antigenics' Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 45: Antisoma's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 46: Ariad's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 47: Arno Therapeutics' Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 48: Array BioPharma's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 49: Asahi Kasei Pharma's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 50: Ascenta Therapeutics' Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 51: Astellas' Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 52: Astex Therapeutics' Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 53: AstraZeneca's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 54: Attenuon's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 55: Bayer's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 56: BioCryst Pharmaceuticals' Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 57: Biogen Idec's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 58: Bioton's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 59: Bioton's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 60: Bristol-Myers Squibb's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 61: BTG's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 62: Calistoga Pharmaceuticals' Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 63: Callisto Pharmaceuticals' Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 64: Celator Pharmaceuticals' Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 65: Cell Genesys' Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 66: Cell Therapeutics' Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 67: Cephalon's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 68: CJ Corp's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 69: Clavis Pharma's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 70: Curacyte's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 71: Cyclacel's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 72: Cylene Pharmaceuticals' Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 73: CytImmune Sciences' Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 74: Cytokinetics' Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 75: Daiichi Sankyo's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 76: Dainippon Sumitomo Pharma's Included Leukemia Pipeline Composition and Competitive Fall-Out. 389

Table 77: Dara Biosciences' Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 78: Deciphera Pharmaceuticals' Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 79: Dong-A's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 80: Eleos' Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 81: Eli Lilly's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 82: Enzon's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 83: EpiCept's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 84: Exelixis' Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 85: ExonHit Therapeutics' Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 86: Gemin X Pharmaceuticals' Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 87: Genentech's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 88: Genmab's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 89: Genta's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 90: Genzyme's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 91: Geron's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 92: GlaxoSmithKline's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 93: Gloucester Pharmaceuticals' Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 94: GlycoGenesys' Included Leukemia Pipeline Composition and Competitive Fall-Out

4 Leukemia - A Competitive Analysis to New Products, Portfolio Planning,

Licensing & Acquisition Through Pipeline Benchmarking

20 Cancer Highlights No 7 Vol 8 2009| BioSeeker Group AB © 2009

Table 95: Hayashibara's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 96: Hoffmann-La Roche's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 97: ImClone Systems' Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 98: Immunomedics' Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 99: Innate Pharma's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 100: Innovive's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 101: Isis Pharmaceuticals' Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 102: Italfarmaco's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 103: Johnson & Johnson's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 104: Kanisa's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 105: Kyowa Hakko Kirin's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 106: LG Life Sciences' Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 107: Lorus Therapeutics' Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 108: MAT Biopharma's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 109: MaxCyte's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 110: Meda's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 111: Medarex's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 112: MethylGene's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 113: Micromet's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 114: MorphoSys' Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 115: NanoMed Pharmaceuticals' Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 116: Nerviano Medical Sciences' Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 117: NIH's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 118: Nippon Shinyaku's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 119: Novartis' Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 120: Novogen's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 121: PDL BioPharma's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 122: Peplin's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 123: Pfizer's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 124: Pharmacyclics' Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 125: PharmaMar's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 126: PIERIS Proteolab's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 127: Rigel's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 128: Sanofi-Aventis' Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 129: Santaris Pharma's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 130: SBIO's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 131: Schering-Plough's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table of Contents 4

BioSeeker Group AB © 2009 | www.bioseeker.com 21

Table 132: SciGen's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 133: Seattle Genetics' Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 134: Sepal Pharma's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 135: Servier's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 136: Shantha Biotechnics' Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 137: Sidus' Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 138: Spirogen's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 139: Stemline Therapeutics' Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 140: SuperGen's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 141: Supratek Pharma's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 142: Swedish Orphan's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 143: SymBio Pharmaceuticals' Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 144: Takeda's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 145: Teva's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 146: TopoTarget's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 147: Trion Pharma's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 148: Trubion's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 149: Vertex Pharmaceuticals' Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 150: Vion Pharmaceuticals' Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 151: VioQuest's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 152: Wyeth's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 153: Yamasa Corporation's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 154: Zenyaku Kogyo's Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 155: ZymoGenetics' Included Leukemia Pipeline Composition and Competitive Fall-Out

Table 156: Non-industrial Sources' Included Leukemia Pipeline Composition and Competitive Fall-Out

Abstract

This report includes defined and up to date development strategies for 175 leukemia drugs (>250 projects) within the portfolio of 126 investigators, from Preclinical to Marketed. Leukemia drugs are further dived into the sub-indications of ALL, AML, CLL, CML, HCL and MCL. The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It serves as an external commercial advocate for pharmaceutical companies’ portfolio planning and new product planning by:
  • Providing competitive input to the R&D organization to guide development of early product
    • ideas and ensure efforts are aligned with business objectives
  • Analyzing, correlating and integrating valuable data sources in order to provide accurate data
    • for valuation of pipeline, in-licensing and new business opportunities
  • Providing commercial analytic support for due diligence on in-licensing and acquisition opportunities
This report will also be an important part of creating and implementing a market development plan for any leukemia drugs to ensure that the optimal market conditions exist by the time the product is commercialized. BioSeeker’s leukemia pipeline evaluation of development options, competitive landscape and positioning is derived through extensive pipeline benchmarking analysis, including: Single Drug Target Analysis of 136 Drug Targets
  • Highlighting twelve themes about the drug target (i.e. Drugs and investigators sharing a
    • particular target, Types of compounds aimed at a specific target, Protein-protein interactions of a specific target with other known leukemia drug targets, Pathway involvement of a drug target, Presence of structural and protein expression data of a target etc.)
  • Supportive chapters on selected drug themes above
    • Competitive Landscape Analysis based on 115 Identified Drug Target Combinations
  • Identifies New and Unique leukemia drugs by developmental stage
  • Head-to-head targeting competition
  • Targeting competition by at least 50% bi-directional drug target combination match
  • Clinical validation and progress on all identified drug target combinations
    • Competitive Landscape Analysis based on Compound Strategies at Work
  • Identifies New and Unique leukemia drugs based on six different compound strategies (Small
    • molecules, Peptide/Protein, Antibody, Nucleic acid therapies, Gene therapy and Reformulation drugs)
  • Head-to-head targeting competition
  • Targeting competition by at least 50% bi-directional drug target combination match
    • Competitive Benchmarking of Leukemia Pipeline by 126 Investigators
  • Competitive Fall-out table for each of the included investigators’ leukemia pipeline, overlaid
    • with head-to-head targeting competitors’ drugs
  • Competitive summary profile for each one of the 175 included leukemia drugs


Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report

Price and Delivery Options
See related reports or call the number above for help from a research specialist.


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 300,000 market research reports, company profiles and country profiles from over 700 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2012
2/14/2012 - 31